| Item Type | Name |
|
Concept
|
Antigens, Differentiation, T-Lymphocyte
|
|
Concept
|
T-Lymphocytes, Cytotoxic
|
|
Concept
|
T-Lymphocytes, Helper-Inducer
|
|
Concept
|
Lymphocyte Activation
|
|
Concept
|
CD8-Positive T-Lymphocytes
|
|
Concept
|
Lymphocyte Count
|
|
Concept
|
T-Lymphocytes, Regulatory
|
|
Concept
|
CD4-Positive T-Lymphocytes
|
|
Concept
|
B-Lymphocytes
|
|
Concept
|
T-Lymphocyte Subsets
|
|
Concept
|
Epitopes, T-Lymphocyte
|
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Lymphocyte Culture Test, Mixed
|
|
Academic Article
|
Thymus-leukemia antigen interacts with T cells and self-peptides.
|
|
Academic Article
|
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.
|
|
Academic Article
|
Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
|
|
Academic Article
|
Mechanisms of T-cell inhibition: implications for cancer immunotherapy.
|
|
Academic Article
|
Cancer immunotherapy: sipuleucel-T and beyond.
|
|
Academic Article
|
Expansion of natural (NK1+) T cells that express alpha beta T cell receptors in transporters associated with antigen presentation-1 null and thymus leukemia antigen positive mice.
|
|
Academic Article
|
An increased gamma delta T cell population in the intestine of thymus-leukemia antigen transgenic mice.
|
|
Academic Article
|
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues.
|
|
Academic Article
|
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
|
|
Academic Article
|
Identification of human regulatory T cells in the setting of T-cell activation and anti-CTLA-4 immunotherapy on the basis of expression of latency-associated peptide.
|
|
Academic Article
|
Advances in the development of cancer immunotherapies.
|
|
Academic Article
|
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
|
|
Academic Article
|
Cancer immunotherapy: in vivo imaging of adoptively transferred T cells in an immunocompetent host.
|
|
Academic Article
|
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.
|
|
Academic Article
|
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.
|
|
Academic Article
|
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.
|
|
Academic Article
|
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
|
|
Academic Article
|
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
|
|
Academic Article
|
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy.
|
|
Academic Article
|
CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
|
|
Academic Article
|
The future of immune checkpoint therapy.
|
|
Academic Article
|
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
|
|
Academic Article
|
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
|
|
Academic Article
|
Strategies for combining immunotherapy with radiation for anticancer therapy.
|
|
Academic Article
|
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
|
|
Academic Article
|
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy.
|
|
Academic Article
|
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
|
|
Academic Article
|
ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
|
|
Academic Article
|
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
|
|
Academic Article
|
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
|
|
Academic Article
|
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
|
|
Academic Article
|
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
|
|
Academic Article
|
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.
|
|
Academic Article
|
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.
|
|
Academic Article
|
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
|
|
Academic Article
|
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
|
|
Academic Article
|
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
|
|
Academic Article
|
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
|
|
Academic Article
|
Effective combinatorial immunotherapy for castration-resistant prostate cancer.
|
|
Academic Article
|
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
|
|
Academic Article
|
The emerging role of immune checkpoint based approaches in AML and MDS.
|
|
Academic Article
|
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
|
|
Academic Article
|
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies.
|
|
Academic Article
|
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.
|
|
Academic Article
|
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
|
|
Academic Article
|
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.
|
|
Academic Article
|
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
|
|
Academic Article
|
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.
|
|
Academic Article
|
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States.
|
|
Academic Article
|
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
|
|
Concept
|
Intraepithelial Lymphocytes
|
|
Academic Article
|
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response.
|
|
Academic Article
|
Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
|
|
Academic Article
|
Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.
|
|
Academic Article
|
Characterization and Comparison of GITR Expression in Solid Tumors.
|
|
Academic Article
|
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
|
|
Academic Article
|
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy.
|
|
Academic Article
|
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
|
|
Academic Article
|
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
|
|
Academic Article
|
Dissecting the mechanisms of immune checkpoint therapy.
|
|
Academic Article
|
B cells and tertiary lymphoid structures promote immunotherapy response.
|
|
Academic Article
|
Comprehensive T cell repertoire characterization of non-small cell lung cancer.
|
|
Academic Article
|
Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.
|
|
Academic Article
|
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
|
|
Academic Article
|
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.
|
|
Academic Article
|
A composite T?cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events.
|
|
Academic Article
|
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
|
|
Academic Article
|
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
|
|
Academic Article
|
ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype.
|